The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study.
 
Bernard J. Escudier
Honoraria - Bayer; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Exelixis; GlaxoSmithKline; Novartis; Pfizer
 
Thomas Powles
Consulting or Advisory Role - Exelixis; GlaxoSmithKline; Novartis
Research Funding - Exelixis; Genentech; GlaxoSmithKline; Novartis
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Thomas Olencki
Consulting or Advisory Role - Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Pfizer (Inst); TRACON Pharma (Inst)
 
Osvaldo Rudy Aren
No Relationships to Disclose
 
Stephane Oudard
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer; Roche
Speakers' Bureau - Genentech
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Sergio Bracarda
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Piotr Tomczak
No Relationships to Disclose
 
Daniel E. Castellano
No Relationships to Disclose
 
Leonard Joseph Appleman
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Cerulean Pharma; Exelixis
 
Harry A. Drabkin
No Relationships to Disclose
 
Daniel A. Vaena
Research Funding - Acerta Pharma (Inst); Argos Therapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche/Genentech (Inst); Tekmira (Inst); TRACON Pharma (Inst)
 
Steven Milwee
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
Travel, Accommodations, Expenses - Exelixis
 
Jillian Youkstetter
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)